QUILT-3.063: A Study of N-803, haNK and Avelumab in Patients With Merkel Cell Carcinoma That Has Progressed After Checkpoint Therapy
Study sponsor: ImmunityBio, Inc. · IBRX
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2021-09-29Actual
Enrollment · participants9Actual
Source updated2024-08-09Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.